Viewing Study NCT06559137



Ignite Creation Date: 2024-10-26 @ 3:38 PM
Last Modification Date: 2024-10-26 @ 3:38 PM
Study NCT ID: NCT06559137
Status: NOT_YET_RECRUITING
Last Update Posted: None
First Post: 2024-08-15

Brief Title: Evaluation of Pain Management After Surgery When Using Nerve Blocks in the Pediatric Population
Sponsor: None
Organization: None

Study Overview

Official Title: Prospective Evaluation of Post-operative Pain Management Using Peripheral Nerve Blocks in the Pediatric Population
Status: NOT_YET_RECRUITING
Status Verified Date: 2024-08
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: No
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The goal of this randomized clinical trial is to determine if single-shot ropivacaine peripheral nerve blocks PNB - perineural injections for anterior cruciate ligament ACL reconstruction procedures in pediatric orthopaedic sports medicine patients provides significant pain relief and decreased narcotic use The main questions it aims to answer are

Does ropivacaine significantly reduce Visual Analog Scale VAS pain scores and pain levels up to one week postoperatively
Does ropivacaine significantly decrease narcotic use number of pills taken up to one week postoperatively

Researchers will compare the pain outcomes and narcotic use of participants who receive a single-shot ropivacaine peripheral nerve block to those of participants who do not receive a single-shot ropivacaine peripheral nerve block for their ACL reconstruction surgery The goal is to understand if there is a significant difference in participant pain outcomes and narcotic use outside the first 24 hours postoperatively

Participants will

receive either a single-shot ropivacaine peripheral nerve block intraoperatively or no peripheral nerve block during their ACL Quadriceps tendon graft or bone patellar tendon bone graft reconstruction surgery
receive and complete questionnaires at postoperative days 1 4 and 7 regarding their pain scores levels and outcomes effective pain treatments overall pain interference narcotic use number of pills taken and overall pain treatment satisfaction
receive and complete secondary outcome measures of functional and psychological outcomes regarding their ACL reconstruction surgery at postoperative day 1
Detailed Description: This is a single institution prospective single-blinded participant randomized controlled trial to investigate the safety and pain-control efficacy and patient reported pain outcomes of PNBs in youth receiving anterior cruciate ligament reconstruction ACLR As ACLR procedures are a frequent and standardized procedure at this institution choosing to exclusively study this population offers a homogenous and plentiful sample Pain protocols will follow a standard outline used by all participating surgeons to reduce variability between participants The randomization technique of this study is supported by the equipoise of this institutions physicians regarding peripheral nerve blocks and the quantity of participants who this studys results will affect

Participant will be approached pre-operatively for participation after which the surgical team will be informed Participants will be offered the choice to participate in the study and randomize their treatment group If participants do not want their treatment to be randomized they will not be included in the study Participants enrolled in this study will receive either a single-shot ropivacaine peripheral nerve block intraoperatively or no single-shot ropivacaine peripheral nerve block intraoperatively during their ACL reconstruction surgery At post-operative days 1 4 and 7 participants will receive and complete questionnaires regarding their pain scores levels and outcomes effective pain treatments overall pain interference narcotic use number of pills taken and overall pain treatment satisfaction Additionally participants may receive and complete secondary outcome measures of functional and psychological outcomes regarding their ACL reconstruction surgery

As per the institutional pain management protocol participants will receive the following anesthesia doses by body weight BW

Pre-operatively

Regardless of age 05 mg midazolam per kg BW intravenous 15 mg maximum
If patient has history of post-operative nausea and vomiting PONV 040 mg Emend per kg BW pill and 2 mg midazolam intravenous

Intra-operatively

05-10 mg Lidocaine per kg BW intravenous 80 mg maximum
3-4 mg Propofol per kg BW
1-2 mcg Fentanyl per kg BW maximum 100 mcg
035 mg Ketamine per kg BW single dose or titration
01 mg Dexamethasone per kg BW maximum 10 mg

Local Infiltration

If 40 kg 4 mg Exparel per kg BW and 30 mL 09 normal saline
If 40-70 kg 10 mL Exparel 10 mL 025 Marcaine and 10 mL 09 normal saline
If 70 kg 20 mL Exparel and 10 mL 025 Marcaine

Optional

10-20 mcg Dexmedetomidine per kg BW for persistent tachycardia
If intubatedventilated 05-06 mg Rocuronium per kg BW 2 mgkg sugammadex for reversal
If Tranexamic Acid administered 15 mg per kg BW 10-15 min intravenous maximum 1 g
For maintenance 1 Minimum Alveolar Concentration MAC Sevoflurane and 15 mg Acetaminophen per kg BW maximum 1 g
If necessary during emergence 0004-0005 mg hydromorphone per kg BW 05 mg Ketorolac per kg BW maximum 30 mg and 01 mg Ondansetron per kg BW maximum 4 mg
If post-anesthesia care unit PACU Phase 1 medication required 0004-0006 mg hydromorphone per kg BW and 010-015 mg Oxycodone per kg BW
If PACU Phase 2 medication required Metoclopramide Dexamethasone Promethazine or Ondansetron

Post-Operatively

If 12 years

Alternate weight-adjusted Acetaminophen and Ibuprofen every 3 hours
Rescue Weight-adjusted AcetaminophenHydrocodone substituted for Acetaminophen for severe pain every 6 hours maximum 8 doses

If 12 years

Days 1-3 Alternate weight-adjusted Acetaminophen and 10 mg Ketorolac every 3 hours
Days 4-7 Alternate weight-adjusted Acetaminophen and Ibuprofen every 3 hours
Days 1-5 40 mg Famotidine every 12 hours
Rescue Weight-adjusted Tramadol taken with Acetaminophen for severe pain every 6 hours maximum 8 doses

The investigators will enroll 80 participants in each treatment group with 65 in each group needed for a sufficiently powered analysis

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None